|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM214932559 |
| 003 |
DE-627 |
| 005 |
20231224024531.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.12.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0716.xml
|
| 035 |
|
|
|a (DE-627)NLM214932559
|
| 035 |
|
|
|a (NLM)22284392
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Barr, Paul M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.04.2012
|
| 500 |
|
|
|a Date Revised 16.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2012 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Cell signaling initiated by the B cell receptor is critical to normal development of B lymphocytes, most notably at the transitional B cell stage. Inhibition of this signaling pathway with the syk inhibitor, fostamatinib, has produced significant efficacy in lymphoid malignancies and autoimmune conditions. Here, we demonstrate that short-term use of fostamatinib impairs B lymphocyte development at the transitional stage without affecting mature B cell populations. Additionally, IL-10 producing B cells remained relatively constant throughout the treatment period. These findings provide insight into the mechanism of action of B cell receptor inhibition in autoimmune disease. As the development of agents targeting B cell receptor signaling proceeds, monitoring for long-term consequences as well as functional evaluation of B cell subsets may further improve our understanding of this rapidly growing class of novel agents
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Aminopyridines
|2 NLM
|
| 650 |
|
7 |
|a IL10 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Intracellular Signaling Peptides and Proteins
|2 NLM
|
| 650 |
|
7 |
|a Morpholines
|2 NLM
|
| 650 |
|
7 |
|a Oxazines
|2 NLM
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Pyridines
|2 NLM
|
| 650 |
|
7 |
|a Pyrimidines
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Protein-Tyrosine Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a SYK protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a Syk Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a fostamatinib
|2 NLM
|
| 650 |
|
7 |
|a SQ8A3S5101
|2 NLM
|
| 700 |
1 |
|
|a Wei, Chungwen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roger, James
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schaefer-Cutillo, Julia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kelly, Jennifer L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rosenberg, Alexander F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jung, John
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sanz, Iñaki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Friedberg, Jonathan W
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 142(2012), 3 vom: 27. März, Seite 237-42
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:142
|g year:2012
|g number:3
|g day:27
|g month:03
|g pages:237-42
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.12.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 142
|j 2012
|e 3
|b 27
|c 03
|h 237-42
|